SLXN Key Statistics, Chart & Performance
The current stock price of SLXN is 2.29 USD. In the past month the price decreased by -20.76%. In the past year, price decreased by -92.73%.
SLXN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About SLXN
Company Profile
Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The firm is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Company Info
SILEXION THERAPEUTICS CORP
12 Abba Hillel Road
Ramat Gan IL
Employees: 11
Phone: 97286286005
SILEXION THERAPEUTICS CORP / SLXN FAQ
What does SILEXION THERAPEUTICS CORP do?
Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The firm is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
What is the stock price of SILEXION THERAPEUTICS CORP today?
The current stock price of SLXN is 2.29 USD. The price decreased by -2.97% in the last trading session.
Does SLXN stock pay dividends?
SLXN does not pay a dividend.
How is the ChartMill rating for SILEXION THERAPEUTICS CORP?
SLXN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of SILEXION THERAPEUTICS CORP (SLXN) based on its PE ratio?
SILEXION THERAPEUTICS CORP (SLXN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-322.5).
Can you provide the number of employees for SILEXION THERAPEUTICS CORP?
SILEXION THERAPEUTICS CORP (SLXN) currently has 11 employees.
SLXN Technical Analysis
SLXN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SLXN. SLXN has a bad profitability rating. Also its financial health evaluation is rather negative.
SLXN Financial Highlights
Over the last trailing twelve months SLXN reported a non-GAAP Earnings per Share(EPS) of -322.5. The EPS increased by 83.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.62% | ||
| ROE | -132.54% | ||
| Debt/Equity | 0.22 |
SLXN Forecast & Estimates
7 analysts have analysed SLXN and the average price target is 9.18 USD. This implies a price increase of 300.87% is expected in the next year compared to the current price of 2.29.